Medical Cannabis Operators Face New Federal Compliance Costs as Schedule III Shift Advances

By A.J. Herrington, Featured Writer

Medical cannabis companies are preparing for a new layer of federal oversight as regulators advance a proposal to reclassify marijuana as a Schedule III substance. The shift is expected to deliver long-sought relief from 280E, but operators and accountants say the transition will also introduce federal registration fees, security requirements, and recordkeeping obligations that many state-licensed businesses have never had to meet.

The emerging picture suggests a tradeoff: meaningful tax savings paired with new compliance costs that could reshape margins, staffing, and facility operations across the medical cannabis sector.

According to Bloomberg Tax analysis, DEA registration alone could cost thousands of dollars per location, based on current Schedule III fee schedules and depending on how the agency ultimately classifies cannabis businesses. Manufacturers of Schedule III substances currently pay more than $3,000 for a three-year registration, while distributors pay roughly $1,800. Dispensaries could face additional fees if they are treated as controlled-substance handlers, and operators should expect new security, inventory, and recordkeeping standards modeled on existing DEA frameworks.

Bloomberg Tax also raises the possibility that FDA-aligned dispensing rules could apply to some medical cannabis activity. That could include elements such as pharmacist oversight, stricter storage protocols, or new facility certifications, all of which would add to operational costs beyond registration fees. Larger multistate operators with centralized compliance teams are positioned to absorb the shift, while smaller medical dispensaries may face tougher decisions as federal requirements come into focus.

To better understand how the changes may affect patients and operators, I reached out to Thomas Andersen, co-founder and vice president of BTA Cannabis CPA Tax.

Research Gains Could Deliver Long-Term Patient Benefits

Asked about the value of rescheduling for medical cannabis patients, Andersen said the biggest impact may come from expanded research opportunities.

“The DOJ rescheduling order from Schedule I to III will unlock more research and encourage investment into R&D of novel medical therapies,” he said in a written interview. Patients, he added, stand to benefit from more targeted formulations, especially those built around non-intoxicating minor cannabinoids that have been difficult to study under Schedule I.

Compliance Costs Will Fall Unevenly Across the Industry

On the business side, Andersen expects the financial impact to vary widely.

“For big pharma producing FDA-approved drugs, the costs of regulatory compliance with Schedule III will be insignificant,” he wrote. Large MSOs with strong medical footprints, including those in states like Florida, are also positioned to adapt their existing infrastructure.

“Ultimately, compliance costs will cause smaller MSOs and stand-alone mom-and-pop stores to suffer,” he said.

Andersen noted that DEA registration fees are only the start. The larger unknowns include whether dispensaries will need a PharmD or pharmacy technician on staff, what new facility qualifications may be required, and how standard operating procedures will need to change if FDA dispensing guidelines are applied. He also pointed to the likelihood of increased accounting and reporting burdens if federal rules create a bifurcated system separating federally registered medical operations from adult-use businesses.

Operators Should Begin Modeling Costs Now

With many details still pending ahead of the June hearings, Andersen recommends that companies start preparing immediately.

“I think cannabis operators should run financial models for anticipated additional costs against the tax savings,” he said. That includes estimating the cost of new compliance projects and determining how long it will take to design, implement, and maintain updated systems and SOPs.

The companies that quantify the impact early, he said, will be the ones best positioned to navigate the transition.